Serendex held its Extraordinary General Meeting, 1 July 2016, at the company's premises in Hørsholm.

For download EFG Protokollat

For further information, please contact :

Kim Arvid Nielsen
CEO
E-mail: kan@serendex.com

About Serendex Pharmaceuticals A/S

Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP (pulmonary alveolar proteinosis) and ARDS (acute respiratory distress syndrome). These conditions are acute or chronic and have no existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained orphan drug designation (ODD) for several indications in both Europe and USA. The company's sole business focus is drug repositioning, i.e. finding new indications and administration routes for existing drugs. Serendex Pharmaceuticals is listed on Oslo Axess until 3 May 2016. Please visitwww.serendex.com to learn more.

Serendex Pharmaceuticals A/S published this content on 12 July 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 July 2016 07:58:03 UTC.

Original documenthttp://www.serendex.com/minutes-of-serendexs-extraordinary-general-meeting-2016/

Public permalinkhttp://www.publicnow.com/view/8A87309F1E955D2D342A4EB972A945F60241DB40